{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:41Z","timestamp":1791869141470,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR300740"],"award-info":[{"award-number":["NIHR300740"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8225\/A21133"],"award-info":[{"award-number":["C8225\/A21133"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000769","name":"Oxford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ijrobp.2021.10.151","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T21:06:19Z","timestamp":1636405579000},"page":"913-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8575-2145","authenticated-orcid":false,"given":"Georgios","family":"Ntentas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Dedeckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Andrlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne C.","family":"Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Ramroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Kube\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. George","family":"Mikhaeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.10.151_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0003","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"Van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0004","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0005","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.3324\/haematol.2014.108258","article-title":"Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma","volume":"99","author":"Morton","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0006","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0007","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0008","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: A comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2018.08.017","article-title":"Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma","volume":"129","author":"Starke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0012","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0013","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.20.00264","article-title":"Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016","volume":"38","author":"Dores","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0014","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.16232","article-title":"No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy","volume":"188","author":"Lagerl\u00f6f","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma","volume":"97","author":"Conway","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0016","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.prro.2019.01.006","article-title":"Clinical intensity modulated proton therapy for hodgkin lymphoma: which patients benefit the most?","volume":"9","author":"Ntentas","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0018","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.adro.2020.08.004","article-title":"Effect of deep inspiration breath hold on normal tissue sparing with intensity modulated radiation therapy versus proton therapy for mediastinal lymphoma","volume":"5","author":"Moreno","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0019","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0021","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.radonc.2017.01.008","article-title":"A cardiac contouring atlas for radiotherapy","volume":"122","author":"Duane","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0022","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijrobp.2020.07.175","article-title":"Is 5 mm CTV-PTV margin adequate for mediastinal lymphoma treated in DIBH?","volume":"108","author":"Swarnkar","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0023","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2019.05.009","article-title":"Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients","volume":"138","author":"Levis","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0024","unstructured":"World Health Organization. Mortality database. Available at: https:\/\/www.who.int\/healthinfo\/mortality_data\/en\/. Accessed January 1, 2017."},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0025","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/djp147","article-title":"Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma","volume":"101","author":"De Bruin","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0026","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bmj.321.7257.323","article-title":"Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies","volume":"321","author":"Peto","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0027","article-title":"Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis","volume":"10","author":"Field","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0028","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2017.07.033","article-title":"Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and\/or deep inspiration breath hold","volume":"125","author":"Rechner","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0029","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0030","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.2147\/OTT.S220730","article-title":"Proton therapy for lymphomas: Current state of the art","volume":"12","author":"Ricardi","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0031","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0032","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11912-017-0592-7","article-title":"Optimal therapy for early-stage Hodgkin's lymphoma: Risk adapting, response adapting, and role of radiotherapy","volume":"19","author":"Filippi","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0033","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.prro.2019.09.015","article-title":"The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era","volume":"10","author":"Hoppe","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0034","doi-asserted-by":"crossref","first-page":"12074","DOI":"10.1200\/JCO.2021.39.15_suppl.12074","article-title":"Anthracycline exposure and breast cancer risk in female Hodgkin lymphoma survivors","volume":"39","author":"Neppelenbroek","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0035","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jamapediatrics.2019.3807","article-title":"Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use: A report from the Childhood Cancer Survivor Study","volume":"173","author":"Veiga","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0036","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0037","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.21.00408","article-title":"Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography-directed therapy for early-stage Hodgkin lymphoma","volume":"39","author":"Cutter","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0038","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2020.08.022","article-title":"Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction","volume":"153","author":"Ntentas","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.10.151_bib0039","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2014.11.021","article-title":"Relating proton treatments to photon treatments via the relative biological effectiveness - Should we revise current clinical practice?","volume":"91","author":"Paganetti","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621030741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621030741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:58:54Z","timestamp":1759744734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621030741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0360301621030741"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.10.151","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.10.151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}